Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis (Nasdaq: EXEL) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Exelixis' business and see what CAPS investors are saying about the stock right now.

Exelixis facts

Headquarters (Founded) San Francisco (1994)
Market Cap $650 million
Industry Biotechnology
Trailing-12-Month Revenue $237 million
Management Co-Founder/Chairman Dr. Stelios Papadopoulos
President/CEO Dr. Michael Morrissey
Trailing-12-Month Return on Capital 20.1%
Cash/Debt $223 million / $210 million
Competitors AstraZeneca
Genentech
Novartis

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96.5% of the 2,568 members who have rated Exelixis believe the stock will outperform the S&P 500 going forward.  

A couple of weeks ago, one of those bulls, aleax, tapped Exelixis as a rather tempting biotech bet:

They have enough money to complete Phase 3 studies for cabozantinib and get FDA approval (cabo is basically all the company's about by now, as they've focused totally on it). The trials so far are extremely positive; getting approval (and moving on to other forms of cancer) will take years, and MIGHT fail (so this is a high-risk position), but the probability of success is good and the prospective returns of such success absolutely breathtaking (definitely a multibagger from today's depressed stock price). It's also pretty uncorrelated from "the market in general", a pleasing rarity in these days of very high correlation among asset classes.

What do you think about Exelixis, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis and Novartis. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.